Bayer AG
BAYRY · OTC
Market closed$13.80$0.200000 (+1.47%)After hours $13.80 · 0.00%
Key statistics
Previous close$13.60
Open$13.76
Day high$13.87
Day low$13.72
52-week high$15.23
52-week low$7.19
Market cap54.23B
Volume163.58K
Average volume1.39M
P/E ratio9.26
Forward P/E—
EPS1.49
Dividend yield+0.23%
Market context
Why it moved
BAYRY shares moved higher as positive sentiment surrounding Bayer's crop science growth prospects in Brazil, combined with a favorable Supreme Court ruling on Roundup weedkiller liability, bolstered investor confidence in the company's outlook.
What is happening
Recent company-specific developments and publisher coverage.
Simply Wall Street · July 19, 2026Is Bayer (XTRA:BAYN) Cheap After Its Clinical Trial Partnerships?High Plains Journal · July 18, 2026Bayer licenses RAGT genetics for hybrid wheat expansionKCUR · July 17, 2026Bayer won its Roundup case. Where does that leave thousands of pending lawsuits?E&E News by POLITICO · July 17, 2026Bayer withdraws request for glyphosate duties after farmer backlashBayer · July 15, 2026Bayer signs licensing agreement with RAGT and begins broad hybrid wheat commercialization by early 2030siGrow News · July 15, 2026Bayer Signs Exclusive Hybrid Wheat Licensing Deal With RAGTApollo Global Management · July 10, 2026Bayer Secures 3.0 Billion Euros to Improve Capital StructureStock Titan · July 1, 2026Bayer spins U.S. glyphosate unit into Ruveon, a new St. Louis business Benzinga · July 2, 2026Bayer Reorganizes US Glyphosate Business after Roundup Legal Win Benzinga · June 26, 2026Marjorie Taylor Greene Says It Is 'Awful' That 'No One Is Standing Up For Cancer Patients' After Bayer Scores Roundup Victory In Supreme Court Benzinga · June 25, 2026What's Going On With The Surge In Bayer Stock Today? Benzinga · June 15, 2026Bayer's AMBELVIST Receives FDA Approval As Lowest-Dose Macrocyclic Gadolinium-Based Contrast Agent For Contrast-Enhanced MRI In Adult And Pediatric CNS And Non-CNS Applicatio Benzinga · June 3, 2026Bayer Says 'Not Now' To Monsanto Spin-Off Amid Ongoing Roundup Legal Battle Benzinga · May 12, 2026Bayer Lowers FY2026 Adj EPS Guidance from $1.25-$1.40 to $1.20-$1.35 vs $1.20 Est; Lowers FY2026 Sales Guidance from $52.387B-$54.715B to $52.109B-$54.451B vs $53.200B Est Benzinga · May 12, 2026Bayer Q1 Adj. EPS $0.79 Beats $0.64 Estimate, Sales $15.697B Beat $15.490B Estimate Benzinga · April 28, 2026Bayer Stock Plunges As Supreme Court Wrestles With Roundup Cancer Suits